Drugs / IMM0306S
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06535412 | Oct 2024 → Dec 2028 expected | systemic lupus erythematosus | ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMM0306S | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06535412 ↗ |
| Route | Subcutaneous | “subcutaneous IMM0306S” NCT06535412 ↗ |